Following a full submission
AWMSG advice |
|||
| Status: Recommended | |||
Fentanyl (PecFent®) is recommended as an option for use within NHS Wales for the management of breakthrough pain in adults who are already receiving maintenance opioid therapy for chronic cancer pain. Fentanyl (PecFent®) should be initiated by, and remain under the supervision of, a specialist physician experienced in the management of opioid therapy in cancer patients. AWMSG is of the opinion that fentanyl (PecFent®) may be suitable for shared care within NHS Wales for the above indication. |
|||
|
|||
Medicine details |
|||
| Medicine name | fentanyl (PecFent®) | ||
| Formulation | nasal spray | ||
| Reference number | 756 | ||
| Indication | Management of breakthrough pain in adults who are already receiving maintenance opioid therapy for chronic cancer pain |
||
| Company | Archimedes Pharma UK Ltd | ||
| BNF chapter | Central nervous system | ||
| Assessment type | Full | ||
| Status | Recommended | ||
| Advice number | 0911 | ||
| NMG meeting date | 09/06/2011 | ||
| AWMSG meeting date | 13/07/2011 | ||
| Ratification by Welsh Government | 01/09/2011 | ||
| Date of issue | 07/09/2011 | ||